4.7 Article

Use of Antistaphylococcal β-Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding

Journal

CLINICAL INFECTIOUS DISEASES
Volume 53, Issue 2, Pages 158-163

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir340

Keywords

-

Funding

  1. Sharp Healthcare Foundation
  2. Cubist Pharmaceuticals
  3. Astellas Pharmaceuticals
  4. Cubist
  5. Pfizer Pharmaceuticals
  6. Astellas
  7. Ortho-McNeil Pharmaceuticals

Ask authors/readers for more resources

We used daptomycin plus antistaphylococcal beta-lactams (ASBL) to clear refractory MRSA bacteremia. In vitro studies showed enhanced daptomycin bactericidal activity, increased membrane daptomycin binding, and decrease in positive surface charge induced by ASBLs against daptomycin nonsusceptible MRSA. Addition of ASBLs to daptomycin may be of benefit in refractory MRSA bacteremia. (Although the official designation is daptomycin nonsusceptiblity, we will use the term daptomycin-resistance in this paper for facility of presentation.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available